Found: 15
Select item for more details and to access through your institution.
Drug resistance to nelarabine in leukemia cell lines might be caused by reduced expression of deoxycytidine kinase through epigenetic mechanisms.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2022, v. 89, n. 1, p. 83, doi. 10.1007/s00280-021-04373-4
- By:
- Publication type:
- Article
Effect of fluconazole on the pharmacokinetics of fuzuloparib: an open-label, crossover study in Chinese healthy male volunteers.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2022, v. 89, n. 1, p. 141, doi. 10.1007/s00280-021-04376-1
- By:
- Publication type:
- Article
Correlation between immune-related adverse events and the efficacy of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer: systematic review and meta-analysis.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2022, v. 89, n. 1, p. 1, doi. 10.1007/s00280-021-04375-2
- By:
- Publication type:
- Article
A translational model-based approach to inform the choice of the dose in phase 1 oncology trials: the case study of erdafitinib.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2022, v. 89, n. 1, p. 117, doi. 10.1007/s00280-021-04370-7
- By:
- Publication type:
- Article
A phase 1b study of erlotinib and momelotinib for the treatment of EGFR-mutated, tyrosine kinase inhibitor-naive metastatic non-small cell lung cancer.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2022, v. 89, n. 1, p. 105, doi. 10.1007/s00280-021-04369-0
- By:
- Publication type:
- Article
Evaluation of the absolute oral bioavailability of the anaplastic lymphoma kinase/c-ROS oncogene 1 kinase inhibitor lorlatinib in healthy participants.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2022, v. 89, n. 1, p. 71, doi. 10.1007/s00280-021-04368-1
- By:
- Publication type:
- Article
4-(N)-Docosahexaenoyl 2', 2'-difluorodeoxycytidine induces immunogenic cell death in colon and pancreatic carcinoma models as a single agent.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2022, v. 89, n. 1, p. 59, doi. 10.1007/s00280-021-04367-2
- By:
- Publication type:
- Article
Population pharmacokinetic and exposure–response analyses of elotuzumab plus pomalidomide and dexamethasone for relapsed and refractory multiple myeloma.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2022, v. 89, n. 1, p. 129, doi. 10.1007/s00280-021-04365-4
- By:
- Publication type:
- Article
Retraction Note to: Linc‑ROR confers gemcitabine resistance to pancreatic cancer cells via inducing autophagy and modulating the miR‑124/PTBP1/PKM2 axis.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Abemaciclib is synergistic with doxorubicin in osteosarcoma pre-clinical models via inhibition of CDK4/6–Cyclin D–Rb pathway.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2022, v. 89, n. 1, p. 31, doi. 10.1007/s00280-021-04363-6
- By:
- Publication type:
- Article
Half-dose glucarpidase as efficient rescue for toxic methotrexate levels in patients with acute kidney injury.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2022, v. 89, n. 1, p. 41, doi. 10.1007/s00280-021-04361-8
- By:
- Publication type:
- Article
Safety of immune checkpoint inhibitors in non-small-cell lung cancer patients with idiopathic interstitial pneumonia: a matched case–control study.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2022, v. 89, n. 1, p. 21, doi. 10.1007/s00280-021-04362-7
- By:
- Publication type:
- Article
Adaptation of lenvatinib treatment in patients with hepatocellular carcinoma and portal vein tumor thrombosis.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2022, v. 89, n. 1, p. 11, doi. 10.1007/s00280-021-04359-2
- By:
- Publication type:
- Article
Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose–escalation phase 1 trial.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2022, v. 89, n. 1, p. 93, doi. 10.1007/s00280-021-04358-3
- By:
- Publication type:
- Article
A phase I study of veliparib with cyclophosphamide and veliparib combined with doxorubicin and cyclophosphamide in advanced malignancies.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2022, v. 89, n. 1, p. 49, doi. 10.1007/s00280-021-04350-x
- By:
- Publication type:
- Article